TScan Reports 100% Relapse-Free Survival in AML Patients Treated with TSC-101 at Two-Year Follow-Up
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 57 minutes ago0mins
- Significant Efficacy: Among patients treated with TSC-101, 100% (3/3) remained relapse-free at the two-year follow-up, compared to only 25% (1/4) in the control group, highlighting TSC-101's potential in treating acute myeloid leukemia (AML).
- Good Safety Profile: No dose-limiting toxicities were observed at any dose level of TSC-101, indicating excellent tolerability among patients and laying a solid foundation for future clinical applications.
- Clinical Trial Progress: The company plans to initiate a pivotal study in the second quarter of 2026 to further validate the efficacy of TSC-101 and expand indications to address unmet medical needs.
- Market Opportunity: With increasing treatment demands for AML and MDS patients, TScan anticipates significantly increasing the addressable patient population by expanding its hematologic malignancies program, enhancing its competitive position in the market.
TCRX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on TCRX
Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
5 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.090
Low
3.00
Averages
5.50
High
7.00
Current: 1.090
Low
3.00
Averages
5.50
High
7.00
Morgan Stanley
Maxwell Skor
Overweight -> Equal Weight
downgrade
2025-11-13
Reason
Morgan Stanley
Maxwell Skor
Price Target
2025-11-13
downgrade
Overweight -> Equal Weight
Reason
Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics to Equal Weight from Overweight. The firm's new base case price target is now $1-$5 vs. $7-$13 prior. After the company's recent strategic prioritization update, the firm plans to remain on the sidelines until there is greater visibility on near-term catalysts, the analyst tells investors in a research note. This change reflects that the pivotal TSC-101 study is now expected to initiate in Q2 of FY26 vs. prior forecast of the second half of FY25, the firm added.
BTIG
Justin Zelin
Buy -> Neutral
downgrade
2025-11-04
Reason
BTIG
Justin Zelin
Price Target
2025-11-04
downgrade
Buy -> Neutral
Reason
BTIG analyst Justin Zelin downgraded TScan Therapeutics to Neutral from Buy without a price target following the company's decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.
Needham
Buy
downgrade
$9 -> $6
2025-11-03
Reason
Needham
Price Target
$9 -> $6
2025-11-03
downgrade
Buy
Reason
Needham lowered the firm's price target on TScan Therapeutics to $6 from $9 and keeps a Buy rating on the shares. TScan is consolidating its efforts on lead heme program TSC-101, with an ASH abstract suggesting some loss of activity with TSC-101 compared to data from last year, the analyst tells investors in a research note. Despite these and other recent challenges, the firm continues to view TSC-101 as an important potential solution for rapid relapse in patients receiving transplant.
Needham
Gil Blum
Strong Buy
Reiterates
$9
2025-04-08
Reason
Needham
Gil Blum
Price Target
$9
2025-04-08
Reiterates
Strong Buy
Reason
See All Ratings
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of Clene Inc.'s CNM-Au8 program for ALS?
Why did Biomea Fusion's stock rise after its icovamenib announcement?
How might TScan's improved manufacturing process impact its future trials?
Will TScan's KOL event increase investor confidence in its ALLOHA trial?